← FDA DRUG APPROVALS

FDA ANDA · ANDA200405

MONTELUKAST SODIUM

Sponsor: LANNETT CO INC

APPLICATION
ANDA200405
TYPE
ANDA
ORIGINAL APPROVAL
2012-08-03
LATEST ACTION
2023-06-26
ROUTE
ORAL
DOSAGE FORM
TABLET, CHEWABLE
MARKETING STATUS
Prescription

Products

MONTELUKAST SODIUMPrescription
MONTELUKAST SODIUM EQ 5MG BASE · TABLET, CHEWABLE · ORAL
MONTELUKAST SODIUMPrescription
MONTELUKAST SODIUM EQ 4MG BASE · TABLET, CHEWABLE · ORAL

Approval history

2023-06-26Labeling · Supplement 17 · standardAP
2023-06-26Labeling · Supplement 16 · standardAP
2020-10-08Labeling · Supplement 14 · standardAP
2020-10-08Labeling · Supplement 12 · standardAP
2020-10-08Labeling · Supplement 10 · standardAP
2018-07-23Labeling · Supplement 9 · standardAP
2016-06-02Labeling · Supplement 6 · standardAP
2016-06-02Labeling · Supplement 5 · standardAP
2013-08-20Labeling · Supplement 3 · standardAP
2013-01-31Labeling · Supplement 2 · standardAP
2012-09-18Labeling · Supplement 1 · standardAP
2012-08-03Not Applicable · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →